Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.

ESC Heart Fail · 2020 · PMC7754779 · PMID 32945624

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, hearts from finerenone‐treated Het mice (1.1 ± 0.2%) showed a trend towards less accumulated damage than untreated Het mice (1.8 ± 0.3%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.